Pfizer Inc.'s fourth-quarter profit fell by half because it sold less Lipitor, the cholesterol fighter that's the biggest drug ever to go off patent, and took some one-time charges.
[See also: 5 best-selling drugs coming off patent]
The landing was softened by cuts in its sales force and other costs, but the drugmaker on Tuesday lowered its 2012 forecast due to the strengthening dollar and bigger-than-expected price cuts in two emerging markets, China and Turkey.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
